

# Medical Policy



## Title: **Positron Emission Tomography (PET) Scanning: Oncologic Applications (Breast and Gynecologic)**

Related Policies:	<ul style="list-style-type: none"> <li>▪ <i>PET Scanning- Oncologic Applications (Genitourinary)</i></li> <li>▪ <i>PET Scanning- Oncologic Applications (Bone and Sarcoma)</i></li> <li>▪ <i>PET Scanning- Oncologic Applications (Hematologic)</i></li> <li>▪ <i>PET Scanning- Oncologic Applications (Lung)</i></li> <li>▪ <i>PET Scanning- Oncologic (Thyroid, Neuroendocrine, Head and Neck)</i></li> <li>▪ <i>PET Scanning- Oncologic Applications (Brain, Melanoma, Unknown Primary)</i></li> <li>▪ <i>PET Scanning- Oncologic Applications (Gastrointestinal and Pancreatic)</i></li> <li>▪ <i>PET Scanning: Cardiac Applications</i></li> <li>▪ <i>PET Scanning: In Oncology to Detect Early Response during Treatment</i></li> <li>▪ <i>PET Scanning: Miscellaneous (Non-cardiac, Non-oncologic) Applications of Fluorine 18 Fluorodeoxyglucose</i></li> </ul>
-------------------	---

<b>Professional / Institutional</b>
Original Effective Date: October 1, 1997 / September 11, 2004
Latest Review Date: February 27, 2025
Current Effective Date: February 27, 2025

**State and Federal mandates and health plan member contract language, including specific provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. To verify a member's benefits, contact [Blue Cross and Blue Shield of Kansas Customer Service](#).**

**The BCBSKS Medical Policies contained herein are for informational purposes and apply only to members who have health insurance through BCBSKS or who are covered by a self-insured group plan administered by BCBSKS. Medical Policy for FEP members is subject to FEP medical policy which may differ from BCBSKS Medical Policy.**

**The medical policies do not constitute medical advice or medical care. Treating health care providers are independent contractors and are neither employees nor agents of Blue Cross and Blue Shield of Kansas and are solely responsible for diagnosis, treatment and medical advice.**

**If your patient is covered under a different Blue Cross and Blue Shield plan, please refer to the Medical Policies of that plan.**

<b>Populations</b>	<b>Interventions</b>	<b>Comparators</b>	<b>Outcomes</b>
<p>Individuals:</p> <ul style="list-style-type: none"> <li>With diagnosed breast cancer and inconclusive results from other imaging techniques</li> </ul>	<p>Interventions of interest are:</p> <ul style="list-style-type: none"> <li>Adjunctive <sup>18</sup>F-FDG-PET or <sup>18</sup>F-FDG-PET/CT for staging or restaging</li> </ul>	<p>Comparators of interest are:</p> <ul style="list-style-type: none"> <li>Conventional imaging techniques</li> </ul>	<p>Relevant outcomes include:</p> <ul style="list-style-type: none"> <li>Test validity</li> </ul>
<p>Individuals:</p> <ul style="list-style-type: none"> <li>With suspected or diagnosed breast cancer and in need of staging or restaging information</li> </ul>	<p>Interventions of interest are:</p> <ul style="list-style-type: none"> <li><sup>18</sup>F-FDG-PET or <sup>18</sup>F-FDG-PET/CT</li> </ul>	<p>Comparators of interest are:</p> <ul style="list-style-type: none"> <li>Conventional imaging techniques</li> </ul>	<p>Relevant outcomes include:</p> <ul style="list-style-type: none"> <li>Test validity</li> </ul>
<p>Individuals:</p> <ul style="list-style-type: none"> <li>Who are asymptomatic after completing breast cancer treatment</li> </ul>	<p>Interventions of interest are:</p> <ul style="list-style-type: none"> <li><sup>18</sup>F-FDG-PET or <sup>18</sup>F-FDG-PET/CT</li> </ul>	<p>Comparators of interest are:</p> <ul style="list-style-type: none"> <li>Conventional imaging techniques</li> </ul>	<p>Relevant outcomes include:</p> <ul style="list-style-type: none"> <li>Test validity</li> </ul>
<p>Individuals:</p> <ul style="list-style-type: none"> <li>With diagnosed cervical cancer and in need of staging or restaging information</li> </ul>	<p>Interventions of interest are:</p> <ul style="list-style-type: none"> <li><sup>18</sup>F-FDG-PET or <sup>18</sup>F-FDG-PET/CT</li> </ul>	<p>Comparators of interest are:</p> <ul style="list-style-type: none"> <li>Conventional imaging techniques</li> </ul>	<p>Relevant outcomes include:</p> <ul style="list-style-type: none"> <li>Test validity</li> </ul>
<p>Individuals:</p> <ul style="list-style-type: none"> <li>With suspected cervical cancer or who are asymptomatic after completing cervical cancer treatment</li> </ul>	<p>Interventions of interest are:</p> <ul style="list-style-type: none"> <li><sup>18</sup>F-FDG-PET or <sup>18</sup>F-FDG-PET/CT</li> </ul>	<p>Comparators of interest are:</p> <ul style="list-style-type: none"> <li>Conventional imaging techniques</li> </ul>	<p>Relevant outcomes include:</p> <ul style="list-style-type: none"> <li>Test validity</li> </ul>
<p>Individuals:</p> <ul style="list-style-type: none"> <li>With diagnosed endometrial cancer in need of staging or restaging information</li> </ul>	<p>Interventions of interest are:</p> <ul style="list-style-type: none"> <li><sup>18</sup>F-FDG-PET or <sup>18</sup>F-FDG-PET/CT</li> </ul>	<p>Comparators of interest are:</p> <ul style="list-style-type: none"> <li>Conventional imaging techniques</li> </ul>	<p>Relevant outcomes include:</p> <ul style="list-style-type: none"> <li>Test validity</li> </ul>
<p>Individuals:</p> <ul style="list-style-type: none"> <li>Who are asymptomatic after completing endometrial cancer treatment</li> </ul>	<p>Interventions of interest are:</p> <ul style="list-style-type: none"> <li><sup>18</sup>F-FDG-PET or <sup>18</sup>F-FDG-PET/CT</li> </ul>	<p>Comparators of interest are:</p> <ul style="list-style-type: none"> <li>Conventional imaging techniques</li> </ul>	<p>Relevant outcomes include:</p> <ul style="list-style-type: none"> <li>Test validity</li> </ul>
<p>Individuals:</p> <ul style="list-style-type: none"> <li>With diagnosed ovarian cancer and in need of staging or restaging information</li> </ul>	<p>Interventions of interest are:</p> <ul style="list-style-type: none"> <li><sup>18</sup>F-FDG-PET or <sup>18</sup>F-FDG-PET/CT</li> </ul>	<p>Comparators of interest are:</p> <ul style="list-style-type: none"> <li>Conventional imaging techniques</li> </ul>	<p>Relevant outcomes include:</p> <ul style="list-style-type: none"> <li>Test validity</li> </ul>

Populations	Interventions	Comparators	Outcomes
Individuals: <ul style="list-style-type: none"> <li>▪ With suspected ovarian cancer or who are asymptomatic after completing ovarian cancer treatment</li> </ul>	Interventions of interest are: <ul style="list-style-type: none"> <li>▪ <sup>18</sup>F-FDG-PET or <sup>18</sup>F-FDG-PET/CT</li> </ul>	Comparators of interest are: <ul style="list-style-type: none"> <li>▪ Conventional imaging techniques</li> </ul>	Relevant outcomes include: <ul style="list-style-type: none"> <li>▪ Test validity</li> </ul>

## DESCRIPTION

Positron emission tomography (PET) scanning uses positron-emitting radionuclide tracers coupled to organic molecules, such as glucose, ammonia, or water, to produce images. The radionuclide tracers simultaneously emit 2 high-energy photons in opposite directions that can be simultaneously detected (referred to as coincidence detection) by a PET scanner, comprising multiple stationary detectors that encircle the area of interest.

## OBJECTIVE

The objective of this evidence review is to examine whether the use of PET for diagnosis, staging and restaging, and/or surveillance improves the net health outcome in individuals with breast or gynecologic cancers.

## BACKGROUND

A variety of tracers are used for positron emission tomography (PET) scanning, including oxygen 15, nitrogen 13, carbon 11 choline, fluorine 18, gallium 68, fluciclovine 18, and copper 64. Because of their short half-life, some tracers must be made locally using an onsite cyclotron. The radiotracer most commonly used in oncology imaging has been fluorine 18 coupled with fluorodeoxyglucose (FDG), which correlates with glucose metabolism. Fluorodeoxyglucose has been considered useful in cancer imaging because tumor cells show increased metabolism of glucose. The most common malignancies studied have been melanoma, lymphoma, lung, colorectal, and pancreatic cancer.

Fluoroestradiol F18 (FES) is another radiotracer using in oncology imaging. FES specifically targets and binds to the estrogen receptor (ER) and its uptake, measured by PET, in breast cancer tumors is directly proportional to tumor ER expression.

This evidence review focuses on the use of radiotracers detected with dedicated PET scanners. Radiotracers, such as FDG, may be detected using single-photon emission computerized tomography cameras, a technique that may be referred to as FDG-single-photon emission computerized tomography imaging. The use of single-photon emission computerized tomography cameras for PET radiotracers presents unique issues of diagnostic performance and is not considered herein.

**REGULATORY STATUS**

As of November 2024, the following radiopharmaceuticals have been granted approval by the U.S. Food and Drug Administration, to be used with PET for breast and gynecologic cancer-related indications (see Table 1).<sup>1</sup>

Cerianna™ is indicated for use with PET for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in individuals with recurrent or metastatic breast cancer. Its limitation of use states that "tissue biopsy should be used to confirm recurrence of breast cancer and to verify ER status by pathology."

**Table 1. Radiopharmaceuticals Approved for Use With PET for Breast and Gynecologic Cancer Applications**

<b>Radiopharmaceutical</b>	<b>Manufacturer</b>	<b>Name</b>	<b>Carcinoma-Related Indication With PET</b>
Fluorine-18 fluorodeoxyglucose (FDG)	Various		Suspected or existing diagnosis of cancer, all types
Fluorine-18 fluoroestradiol (FES)	Zionexa USA	Cerianna™	Detection of ER-positive lesions as an adjunct to biopsy in individuals with recurrent or metastatic breast cancer

ER: estrogen receptor.

**POLICY**

- All policy statements apply to both positron emission tomography (PET) scans and PET plus computed tomography (CT) scans (ie, PET scans with or without PET/CT fusion).
- For the clinical situations indicated that may be considered medically necessary, this assumes that the results of the PET scan will influence treatment decisions. If the results will not influence treatment decisions, these situations would be considered not medically necessary.

**A. Breast Cancer**

1. PET scanning using  $^{18}\text{F}$ -FDG isotope may be considered **medically necessary** in the staging or restaging of breast cancer for the following application:
  - a. Detecting locoregional or distant recurrence or metastasis (except axillary lymph nodes) when suspicion of disease is high and other imaging is inconclusive.
2. PET scanning using  $^{18}\text{F}$ -FDG isotope is considered **experimental / investigational** in the evaluation of breast cancer for all other applications, including but not limited to the following:
  - a. Differential diagnosis in individuals with suspicious breast lesions or an indeterminate or low suspicion finding on mammography.
  - b. Staging axillary lymph nodes.
  - c. Predicting pathologic response to neoadjuvant therapy for locally advanced disease.
3. PET scanning using fluoroestradiol F18 (FES) is considered **experimental / investigational** in individuals with breast cancer (see Policy Guidelines for exceptions).

**B. Cervical Cancer**

1. PET scanning using  $^{18}\text{F}$ -FDG isotope may be considered **medically necessary** in the initial staging of individuals with locally advanced cervical cancer.
2. PET scanning using  $^{18}\text{F}$ -FDG isotope may be considered **medically necessary** in the evaluation of known or suspected recurrence.

**C. Endometrial Cancer**

1. PET scanning using  $^{18}\text{F}$ -FDG isotope is considered **medically necessary** in the:
  - a. Detection of lymph node metastases, and
  - b. Assessment of endometrial cancer recurrence.

**D. Ovarian Cancer**

1. PET scanning using  $^{18}\text{F}$ -FDG isotope may be considered **medically necessary** in the evaluation of individuals with signs and/or symptoms of suspected ovarian cancer recurrence (restaging) when standard imaging, including CT scan, is inconclusive.
2. PET scanning using  $^{18}\text{F}$ -FDG isotope is considered **experimental / investigational** in the initial evaluation of known or suspected ovarian cancer in all situations.

## POLICY GUIDELINES

### Patient Selection

- A. As with any imaging technique, the medical necessity of positron emission tomography (PET) scanning depends in part on what imaging techniques are used before or after the PET scanning. Due to its expense, PET scanning is typically considered after other techniques, such as computed tomography (CT), magnetic resonance imaging (MRI), or ultrasonography, provide inconclusive or discordant results. If so, the medical necessity of subsequent imaging during the same diagnostic evaluation is unclear. Thus, PET should be considered for the medically necessary indications above only when standard imaging (eg, CT, MRI) is inconclusive or not indicated, including situations when an individual has a contraindication to intravenous contrast agents, making initial CT scans unattainable.
- B. Selection criteria for PET scanning may also be complex. Due to the complicated hierarchy of imaging options in individuals with malignancy and complex selection criteria, a possible implementation strategy for this policy is its use for retrospective review, possibly focusing on cases with multiple imaging tests, including PET scans.
- C. Use of PET scanning for surveillance as described in the policy statement and policy rationale refers to the use of PET to detect disease in asymptomatic individuals at various intervals. This is not the same as the use of PET for detecting recurrent disease in symptomatic individuals; these applications of PET are considered within tumor-specific categories in the policy statements.
- D. Use of fluoroestradiol F18 (FES)-PET may be considered in individuals with recurrent or metastatic breast cancer in certain clinical scenarios, such as when a biopsy is inconclusive. Current NCCN guidelines on breast cancer (v.5.2024) state that FES-PET may be considered for estrogen receptor-positive disease.

**Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.**

## RATIONALE

This evidence review has been updated regularly with searches of the PubMed database. The most recent literature update was performed through September 30, 2024.

The review has been informed by multiple evaluations of positron emission tomography (PET), including TEC Assessments, other systematic reviews, meta-analyses, and decision analyses.

Evidence reviews assess whether a medical test is clinically useful. A useful test provides information to make a clinical management decision that improves the net health outcome. That is, the balance of benefits and harms is better when the test is used to manage the condition than when another test or no test is used to manage the condition.

The first step in assessing a medical test is to formulate the clinical context and purpose of the test. The test must be technically reliable, clinically valid, and clinically useful for that purpose.

Evidence reviews assess the evidence on whether a test is clinically valid and clinically useful. Technical reliability is outside the scope of these reviews, and credible information on technical reliability is available from other sources.

Promotion of greater diversity and inclusion in clinical research of historically marginalized groups (e.g., People of Color [African-American, Asian, Black, Latino and Native American]; LGBTQIA (Lesbian, Gay, Bisexual, Transgender, Queer, Intersex, Asexual); Women; and People with Disabilities [Physical and Invisible]) allows policy populations to be more reflective of and findings more applicable to our diverse members. While we also strive to use inclusive language related to these groups in our policies, use of gender-specific nouns (e.g., women, men, sisters, etc.) will continue when reflective of language used in publications describing study populations.

## **POSITRON EMISSION TOMOGRAPHY AND POSITRON EMISSION TOMOGRAPHY PLUS COMPUTED TOMOGRAPHY**

### **Clinical Context and Test Purpose**

For this evidence review, PET and PET plus computed tomography (CT) scanning is discussed for the following 4 applications in oncology: diagnosis, staging, restaging, and surveillance. Diagnosis refers to the use of PET as part of the testing used in establishing whether an individual has cancer. Staging refers to the use of PET to determine the stage (extent) of cancer at the time of diagnosis before any treatment is given. Imaging during staging is generally to determine whether the cancer is localized. This also may be referred to as initial staging. Restaging refers to imaging after treatment in 2 situations. First, restaging is part of the evaluation of an individual in whom disease recurrence is suspected based on signs and/or symptoms. Second, restaging also includes determining the extent of malignancy after completion of a full course of treatment. Surveillance refers to the use of imaging in asymptomatic individuals (individuals without objective signs or symptoms of recurrent disease). Surveillance is completed 6 months or more ( $\geq 12$  months for lymphoma) after completion of treatment.

The following PICO was used to select literature to inform this review.

### ***Populations***

The relevant populations of interest are:

- Individuals who are suspected of having breast or gynecologic cancer.
- Individuals diagnosed with breast or gynecologic cancer and need information on the extent of cancer (initial staging upon diagnosis confirmation or restaging following treatment).
- Individuals with breast or gynecologic cancer who have completed a round of treatment and may be at risk of recurrence.

### ***Interventions***

The test being considered is PET or PET/CT. A PET scan is a nuclear medicine 3-dimensional imaging technique. Radioactive tracers are ingested or injected, and radioactive emissions are detected by an imaging device, allowing observations on blood flow, oxygen use, and metabolic processes around the lesions. When CT is added to PET, the images are superimposed, providing additional anatomic information. The most common radioactive tracer used for oncologic applications is fluorine 18 ( $^{18}\text{F}$ ) fluorodeoxyglucose (FDG).  $^{18}\text{F}$  fluoroestradiol (FES) is also used under certain clinical scenarios, such as determining ER status in recurrent or metastatic lesions

as an adjunct to biopsy, to assess ER status in difficult to biopsy, or to evaluate extent of ER expression in indolent tumors. Radiation exposure from PET and PET/CT is considered moderate to high.

### **Comparators**

The comparators of interest are conventional imaging techniques such as ultrasound, magnetic resonance imaging (MRI), and x-rays.

### **Outcomes**

The general outcomes of interest are related to the clinical validity of PET and PET/CT in (1) diagnosing suspected cancers, (2) providing staging or restaging information, and (3) detecting recurrence following cancer treatment. Clinical validity is most often measured by sensitivity, specificity, positive predictive values (PPV), and negative predictive values (NPV). For the clinical utility of PET and PET/CT to be demonstrated, the tests would need to inform treatment decisions that would improve survival and quality of life.

Clinical validity can be measured as soon as results from PET or PET/CT can be compared with results from conventional imaging techniques. Outcomes for clinical utility are long-term, which, depending on the type of cancer, can range from months or a few years for more aggressive cancers to many years for less aggressive cancers.

### **Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- To assess the clinical validity of PET and PET/CT, studies should report sensitivity, specificity, PPV, and NPV. Additionally, studies reporting false-positive rates and false-negative rates are informative.
- To assess the clinical utility of PET and PET/CT, studies should demonstrate how results of these imaging techniques impacted treatment decisions and overall management of the patient.

### **Clinically Valid**

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

### **Clinically Useful**

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if individuals receive correct therapy or more effective therapy, avoid unnecessary therapy, or avoid unnecessary testing.

### **Direct Evidence**

Direct evidence of clinical utility is provided by studies that have compared health outcomes for individuals managed with and without the test. Because these are intervention studies, the preferred evidence would be from randomized controlled trials (RCTs).

### **Chain of Evidence**

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.



Most of the evidence on the use of PET scanning in oncology focuses on clinical validity (sensitivity, specificity), and consists mostly of systematic reviews and meta-analyses. There are few rigorous studies assessing the impact of PET on clinical utility. A few studies that have reported on changes in staging and/or treatment that result from the PET scan do not evaluate whether these changes resulted in improvements in the net health outcome. Due to the lack of direct evidence for clinical utility, evidence for clinical validity is presented first, followed by clinical guidelines, which help to outline the indications for which clinical utility is supported.

## **REVIEW OF EVIDENCE**

### **BREAST CANCER**

#### **BREAST CANCER DIAGNOSIS**

##### **Systematic Reviews**

Liang et al (2017) conducted a meta-analysis on the use of PET/CT to assess axillary lymph node metastasis.<sup>2</sup> Results from the meta-analyses of 14 studies using MRI and 10 studies using PET/CT showed that MRI had a higher sensitivity in diagnosing axillary lymph node status.

In a meta-analysis of 8 studies (N=873 ) on FDG-PET performed in women with newly discovered suspicious breast lesions, Caldarella et al (2014) reported pooled sensitivity and specificity of 85% (95% CI, 83% to 88%) and 79% (95% CI, 74% to 83%), respectively, on a per lesion basis.<sup>3</sup> As previously noted, a false-negative rate of 15% (100% - sensitivity) may be considered unacceptable given the relative ease of breast biopsy.

A systematic review by Sloka et al (2007) on PET for staging axillary lymph nodes identified 20 studies.<sup>4</sup> Three of these 20 studies were rated high quality, indicating broad generalizability to a variety of individuals and no significant flaws in research methods. The remaining studies were less generalizable due to flaws in the methodology. Reviewers observed that there was great variability in estimates of sensitivity and specificity from the selected studies and that it was difficult to draw conclusions from the evidence.

A TEC Assessment (2001) focused on multiple applications of PET scanning in breast cancer, including characterizing breast lesions, staging axillary lymph nodes, detecting recurrence, and evaluating response to treatment.<sup>5</sup> A TEC Assessment (2003) reexamined all indications except for characterizing breast lesions.<sup>6</sup> The bulk of the data on FDG-PET for breast cancer focuses on its ability to characterize breast lesions further such that individuals could avoid biopsy of a mammographically indeterminate or suspicious lesion. The key statistic in this analysis is the false-negative rate, because individuals with a false-negative result on a PET scan may inappropriately forgo a biopsy and subsequent treatment. The false-negative rate will vary with the underlying prevalence of the disease but may range from 5.5% to 8.5%. Given the relative ease of breast biopsy, this false-negative rate may be considered unacceptable, and thus individuals may undergo biopsy regardless of the results of a PET scan.

##### **Breast Cancer Staging**

Zamanian et al (2023) conducted a meta-analysis of 11 studies (N=753) and reported that the sensitivity and specificity of FDG-PET/CT were greater than bone scintigraphy for detecting bone metastasis in breast cancer individuals.<sup>7</sup> The sensitivity and specificity of FDG-PET/CT were 92%

(95% CI, 88% to 95%) and 99% (95% CI, 96% to 100%) compared with 90% (95% CI, 86% to 93%) and 91% (95% CI, 87% to 94%) for bone scintigraphy, all respectively.

A meta-analysis by Han et al (2021) evaluated the impact of FDG- PET, PET/CT, and PET/MRI on staging and management during the initial staging of breast cancer.<sup>8</sup> A total of 29 studies (N=4276) were identified. The pooled results for all 3 imaging studies demonstrated that they led to a change in staging in 25% (95% CI, 21% to 30%) of individuals and a change in management in 18% (95% CI, 14% to 23%) of individuals.

A meta-analysis by Hong et al (2013) reported a sensitivity and a specificity of FDG-PET/CT in diagnosing distant metastases in breast cancer individuals of 96% (95% CI, 90% to 98%) and 95% (95% CI, 92% to 97%), respectively, based on 8 studies (N=748).<sup>9</sup> In a meta-analysis of 6 comparative studies (n=664 individuals), the sensitivity and specificity were 97% (95% CI, 84% to 99%) and 95% (95% CI, 93% to 97%) with FDG-PET/CT compared with 56% (95% CI, 38% to 74%) and 91% (95% CI, 78% to 97%) with conventional imaging, all respectively.

Rong et al (2013) conducted a meta-analysis of 7 studies (N=668 individuals) and reported that the sensitivity and specificity of FDG-PET/CT were greater than bone scintigraphy for detecting bone metastasis in breast cancer individuals.<sup>10</sup> The sensitivity and specificity of FDG-PET/CT were 93% (95% CI, 82% to 98%) and 99% (95% CI, 95% to 100%) compared with 81% (95% CI, 58% to 93%) and 96% (95% CI, 76% to 100%) for bone scintigraphy, all respectively.

A meta-analysis by Isasi et al (2005) focused on PET for detecting recurrence and metastases.<sup>11</sup> The analysis concluded that PET is a valuable tool; however, they did not compare PET performance with that of other diagnostic modalities, so it is unclear whether the use of PET resulted in different management decisions and health outcomes.

The TEC Assessment (2003) described above in the Breast Cancer Diagnosis section concluded that the use of FDG-PET for staging axillary lymph nodes did not meet TEC criteria.<sup>6</sup>

### **Breast Cancer Restaging**

A systematic review by Xiao et al (2016) evaluated the diagnostic efficacy of FDG-PET and FDG-PET/CT in detecting breast cancer recurrence.<sup>12</sup> The literature search, conducted through January 2016, identified 26 studies (N=1752 ) for inclusion in the analysis; 12 studies used PET and 14 studies used PET/CT. Fourteen studies had QUADAS scores greater than 10. Reasons for suspected recurrence in the 1752 individuals were: elevated tumor markers (57%), suspicion from conventional imaging modalities (34%), and suggestive clinical symptoms or physical examination results (9%). Pooled sensitivity and specificity are presented in Table 2. Subgroup analyses showed that PET/CT was more specific than PET alone in diagnosing recurrent breast cancer (p=.035).

A systematic review by Liu et al (2016) compared FDG-PET or FDG-PET/CT with MRI in assessing pathologic complete response to neoadjuvant chemotherapy in individuals with breast cancer.<sup>13</sup> The literature search, conducted through August 2015, identified 6 studies (N=382) for inclusion. Quality assessment of the studies was deemed satisfactory using the QUADAS-2 scale. Meta-analysis results are presented in Table 2.

In another meta-analysis comparing FDG-PET with MRI and evaluating pathologic complete response to neoadjuvant chemotherapy in individuals with breast cancer, Sheikhabaei et al (2016) selected 10 studies for analysis.<sup>14</sup> The inclusion criteria differed slightly from Liu et al (2016). Liu et al (2016) required that both FDG-PET and MRI be performed before and during (or after) neoadjuvant chemotherapy, while Sheikhabaei et al (2016) did not require the scanning before neoadjuvant chemotherapy. Pooled sensitivities and specificities are listed in Table 2. Subgroup analysis was performed, by the time of scanning (during neoadjuvant chemotherapy and after neoadjuvant chemotherapy was completed).

Other reviews, including Li et al (2018), have also compared MRI with PET or PET/CT in evaluating response to neoadjuvant chemotherapy.<sup>15</sup> Meta-analytic results are similar to previous studies and are presented in Table 2.

**Table 2. Pooled Diagnostic Performance of FDG-PET and MRI in Detection of Residual Disease After Neoadjuvant Chemotherapy for Breast Cancer**

Type of Imaging	No. of Studies ( N )	Sensitivity (95% CI), %	Specificity (95% CI), %
Li et al (2018) <sup>15</sup> ,			
MRI	13 (575)	88 (78 to 94)	69 (51 to 83)
FDG-PET or FDG-PET/CT	13 (618)	77 (58 to 90)	78 (63 to 88)
Xiao et al (2016) <sup>12</sup> ,			
FDG-PET or FDG-PET/CT	26 (1752)	90 (88 to 90)	81 (78 to 84)
Liu et al (2016) <sup>13</sup> ,			
MRI	6 (382)	65 (45 to 80)	88 (75 to 95)
FDG-PET or FDG-PET/CT	6 (382)	86 (76 to 93)	72 (49 to 87)
Sheikhabaei et al (2016) <sup>14</sup> ,			
All studies			
MRI	10 (492)	88 (76 to 95)	55 (41 to 68)
FDG-PET or FDG-PET/CT	10 (535)	71 (52 to 85)	77 (58 to 89)
FDG-PET/CT	7 (385)	82 (62 to 92)	79 (52 to 93)
FDG-PET	3 (150)	43 (26 to 63)	73 (44 to 91)
During neoadjuvant chemotherapy			
MRI	3 (256)	89 (66 to 97)	42 (20 to 68)
FDG-PET/CT	3 (256)	91 (86 to 95)	69 (25 to 93)
After neoadjuvant chemotherapy completion			
MRI	7 (236)	88 (71 to 96)	63 (51 to 74)

Type of Imaging	No. of Studies ( N)	Sensitivity (95% CI), %	Specificity (95% CI), %
FDG-PET or FDG-PET/CT	7 (279)	57 (40 to 71)	80 (65 to 90)
FDG-PET/CT	4 (129)	71 (42 to 89)	88 (73 to 95)

CI: confidence interval; CT: computed tomography; FDG: fluorine 18 fluorodeoxyglucose; MRI: magnetic resonance imaging; PET: positron emission tomography.

Two 2012 meta-analyses pooled studies on the use of FDG-PET to predict pathologic response to neoadjuvant therapy before surgery for locally advanced breast cancer.<sup>16,17</sup> Both reviews reported similar pooled point estimates for sensitivity and specificity. Both concluded that PET had reasonably high sensitivity and relatively low specificity. Neither described how PET should be used to influence patient management decisions and therefore whether health outcomes would be changed relative to decisions not based on PET results. Thus, it is unclear whether PET improves outcomes for predicting pathologic response to neoadjuvant therapy for locally advanced breast cancer.

### Breast Cancer Estrogen Receptor Status

Several studies have investigated the use of FES-PET/CT to determine estrogen receptor (ER) status in individuals with recurrent or metastatic breast cancer.

### Systematic Reviews

Kurland et al (2020) conducted a systematic review and primary meta-analysis on FES-PET of metastatic lesions including 113 nonbreast lesions from 4 studies.<sup>18</sup> For the primary analysis of FES-PET/CT to detect ER-status from metastatic lesions, using immunohistochemistry (IHC) as the reference standard, found a sensitivity of 78% (95%CI, 65% to 88%) and specificity of 98% (95% CI, 65% to 100%). The authors note limitations of this meta-analysis were that inclusion and exclusion criteria for patients and lesions were not clear in all studies and qualitative and quantitative thresholds for <sup>18</sup>F-FES positivity and ER status were not uniform across studies. The authors conclude that tissue sampling limitations, inpatient heterogeneity, and temporal changes in molecular markers may make FES-PET a complement to existing assays.

### Randomized Controlled Trials

Gennari et al (2024) conducted a pilot study of the use of FES-PET/CT in ER-positive/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer comparing first-line endocrine therapy (ET) versus chemotherapy (ChT) (N=147).<sup>19</sup> 117 patients had FES-PET standardized uptake value (SUV)  $\geq 2$  and received ET, and 30 patients had SUV  $< 2$  and were randomized to ET (arm A) or ChT (arm B). These results demonstrated that FES-PET can be used to identify patients classified as endocrine resistant. Those with SUV<sub>max</sub>  $< 2$  who received first-line chemotherapy had improved outcomes compared to first-line endocrine therapy. After median follow-up (62.4 months), 104 (73.2%) patients had disease progression and 53 (37.3%) died. Median progression free survival in patients with SUV  $< 2$  was 12.4 months (95% CI: 3.1 to 59.6) in patients randomized to arm A versus 23.0 months (95% CI: 3.1 to 59.6) in patients randomized to arm B. Median overall survival was 28.2 months (95% CI: 14.2 to not estimable) in arm A versus 52.8 months (95% CI: 16.2 to not estimable) in arm B. The authors noted several limitations. 60-month OS rate was 41.6% (95% CI: 10.4% to 71.1%) in arm A, 42.0% (95% CI: 14.0% to 68.2%) in arm B, and 59.6% (95% CI: 48.6% to 69.0%) in patients with SUV  $\geq 2$ . The study had slow and low accrual due to technical difficulties in activating an international,

multicenter trial. Also, the percentage of patients with FES-PET SUV <2 was lower than expected according to available evidence at the time of study planning.

### **Nonrandomized Clinical Trials**

Ulaner et al (2024) conducted a nonrandomized, single-center phase 2 trial on the use of FES-PET for initial staging and suspected recurrence in ER-positive breast cancer.<sup>20</sup> Patients with ER-positive locally advanced breast cancer (cohort 1; n=62) or suspected recurrence (cohort 2; n=62) were enrolled. Patients underwent standard-of-care imaging (SOC) and FES-PET imaging. In cohort 1, of 14 true-positive findings, SOC detected 12 and FES-PET detected 11 (p>.99). In cohort 2, of 23 true-positive findings, SOC detected 16 and FES detected 18 (p=.77). These results showed no difference between SOC and FES-PET.

van Geel et al (2022) conducted a prospective study on the clinical validity of FES-PET/CT to assess ER status in newly diagnosed metastatic breast cancer (N=181).<sup>21</sup> FES-PET/CT was compared to biopsy. The accuracy of FES-PET/CT to predict biopsied metastasis had a sensitivity of 95% (95% CI, 89% to 97%), a specificity of 80% (66% to 89%), a positive predictive value of 93% (95% CI, 87% to 96%), and a negative predictive value of 85% (95% CI, 72% to 92%). These results demonstrated clinical validity of the use of FES-PET/CT to determine tumor ER status.

Chae et al (2019) conducted a prospective study on the diagnostic accuracy and safety of FES-PET/CT for the assessment of ER status in recurrent or metastatic lesions in patients with breast cancer (N=93).<sup>22</sup> 47 (55%) were oestrogen receptor-positive and 38 (45%) were oestrogen receptor-negative. Positive status percent agreement between the FES-PET/CT results and estrogen receptor status by immunohistochemical assay was 76.6% (95% CI, 62.0% to 87.7%) and the negative status percent agreement was 100.0% (95% CI, 90.8% to 100.0%).

## **GUIDELINES**

### **American College of Radiology**

In 2017, the ACR issued an Appropriateness Criteria for the initial workup and surveillance for local recurrence and distant metastases in asymptomatic women with stage I breast cancer.<sup>23</sup> The ACR noted that FDG-PET/CT is usually not appropriate during initial workup or surveillance of these individuals to rule out metastases.

### **National Comprehensive Cancer Network**

Current NCCN guidelines on breast cancer (v.5.2024) include a category 2B recommendation for FDG-PET/CT as an optional test in the workup of breast cancer.<sup>24</sup> The use of FDG-PET/CT is "most helpful in situations where standard staging studies are equivocal or suspicious. FDG-PET/CT may also be helpful in identifying unsuspected regional nodal disease and/or distant metastases when used in addition to standard staging studies."

The NCCN states FES PET/CT may be considered for ER-positive disease. It does not state the clinical scenarios when FES-PET/CT should be used or which treatment decisions it may inform.

The NCCN recommends against FDG-PET/CT for lower stage breast cancer (I, II, or operable III) due to high false-negative rates in detecting low-grade lesions or lesions less than 1 cm, low

sensitivity in detecting axillary node metastasis, the low prior probability of detectable metastases in these individuals, and high false-positive rates.

The NCCN guidelines do not recommend routine use of PET in asymptomatic individuals for surveillance and follow-up after breast cancer treatment. When monitoring the metastatic disease, the guidelines note that PET is "challenging because of the absence of a reproducible, validated, and widely accepted set of standards for disease activity assessment."

### **Society of Nuclear Medicine and Molecular Imaging**

In 2023, the Society of Nuclear Medicine and Molecular Imaging issued Appropriate Use Criteria for ER-targeted PET imaging with FES.<sup>25</sup> The working group determined FES-PET was appropriate in several clinical scenarios:

- "Assessing ER status in lesions that are difficult to biopsy or when biopsy is nondiagnostic;
- After progression of metastatic disease, for considering second line of endocrine therapy;
- At initial diagnosis of metastatic disease, for considering endocrine therapy;
- Detecting ER status when other imaging tests are equivocal or suggestive."

### **Section Summary: Breast Cancer**

Evidence for the use of PET or PET/CT in individuals with breast cancer consists of TEC Assessments, systematic reviews, and meta-analyses. There is no evidence that PET is useful in diagnosing breast cancer. The false-negative rates of PET in individuals with breast cancer are estimated to be between 5.5% and 8.5%, which can be considered unacceptable, given that breast biopsy can provide more definitive results. Use of PET/CT might be useful in detecting metastases when results from other imaging techniques are inconclusive. The evidence supports the use of FDG-PET and FDG-PET/CT for staging and restaging only if standard staging methods are inconclusive.

The evidence does not support the use of FDG-PET and FDG-PET/CT for diagnosis, staging, and restaging when standard staging methods are conclusive.

The evidence does not support the use of FDG-PET or FDG-PET/CT for surveillance of breast cancer.

The evidence does not support the use of FES-PET for individuals with breast cancer.

## **CERVICAL CANCER**

### **Systematic Reviews**

In a systematic review of 20 studies, Chu et al (2014) reported a pooled sensitivity and specificity for FDG-PET or FDG-PET/CT of 87% (95% CI, 80% to 92%) and 97% (95% CI, 96% to 98%), respectively, for distant metastasis in recurrent cervical cancer.<sup>26</sup> For local-regional recurrence, pooled sensitivity and specificity were 82% (95% CI, 72% to 90%) and 98% (95% CI, 96% to 99%), respectively.

In a meta-analysis of 9 cervical cancer recurrence studies, Rong et al (2013) reported sensitivity and a specificity for PET/CT of 94.8% (95% CI, 91.2% to 96.9%) and 86.9% (95% CI, 82.2% to 90.5%), respectively.<sup>10</sup> Reviewers found the quality of studies on recurrence was average with

some limitations. For example, studies included mostly symptomatic women and did not differentiate between PET for diagnosis or surveillance.

An Agency for Healthcare Research and Quality (AHRQ) review (2008) identified several studies using FDG-PET or FDG-PET/CT to stage advanced cervical cancer and to detect and stage recurrent disease.<sup>27</sup> The report concluded that most studies supported enhanced diagnostic accuracy, which would improve the selection of appropriate treatment for individuals. For recurrent disease, PET identified additional sites of metastasis, which would alter treatment decisions in some cases. For example, in a study by Yen et al (2004) of 55 individuals whose recurrences were initially considered curable with radical surgical treatment, 27 instead underwent palliative therapy based on PET results.<sup>28</sup> An NCCN report conducted by Podoloff et al (2009) also identified several studies supporting the use of PET for initial staging and identifying and staging recurrent disease.<sup>29</sup>

### **Guidelines**

Current NCCN guidelines on cervical cancer (v.4.2024) state that PET/CT may be considered under the following conditions:<sup>30</sup>

- Part of the initial non-fertility and fertility-sparing workup for individuals with stage I cervical cancer.
- Part of the initial staging workup for detection of stage II, III, or IV metastatic disease.
- Follow-up/surveillance for stage I (only nonfertility sparing) through stage IV at 3 to 6 months after completion of therapy or if there is suspected recurrence or metastases.
- To assess response or determine future therapy in individuals with Stage IVB or cervical cancer recurrence.
- PET/CT should cover neck, chest, abdomen, pelvis, and groin.

### **Section Summary: Cervical Cancer**

Evidence for the use of PET in individuals with cervical cancer consists of systematic reviews and meta-analyses. Pooled results have shown that PET can be used for staging or restaging and detecting recurrent disease. The evidence supports the use of FDG-PET and FDG-PET/CT for the diagnosis and staging and restaging of cervical cancer.

The evidence does not support the use of FDG-PET and FDG-PET/CT for surveillance of cervical cancer.

### **SUPPLEMENTAL INFORMATION**

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

### **Practice Guidelines and Position Statements**

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

Current National Comprehensive Cancer Network, American College of Radiology, and other relevant U.S.-based guidelines are summarized in each section of the Rationale.

**U.S. Preventive Services Task Force Recommendations**

Not applicable.

**Ongoing and Unpublished Clinical Trials**

A search of [ClinicalTrials.gov](https://clinicaltrials.gov) in November 2024 identified a large number of ongoing and unpublished trials that might influence this review (Table 4).

**Table 4. Summary of Key Trials**

<b>NCT No.</b>	<b>Trial Name</b>	<b>Planned Enrollment</b>	<b>Completion Date</b>
<b><i>Ongoing</i></b>			
NCT06232122	Evaluation of 68Ga-FAPI-46 and 18F-FDG PET/CT Imaging for Detecting Recurrent Tumor Lesions in Patients of Ovarian Cancer With CA125 Elevation From Complete Response After Therapy	45	Jul 2028
NCT06072807	Brain [18F]-FES PET/CT in the Diagnosis, Treatment Planning and Response Assessment of Brain Metastases in Patients With Estrogen-Receptor Positive Breast Cancer	20	Dec 2026
NCT02285192	Positron Lymphography Via Intracervical 18F-FDG Injection for Pre-surgical Lymphatic Mapping in Stage IB1 Cervical Cancer and High-grade Endometrial Cancer	42	Nov 2025 (active, not recruiting)
NCT05824247	A Prospective Cohort Study of 68ga-FAPI-pet-ct Versus FDG-pet-ct for Ovarian Cancer	60	Jun 2025
NCT05486182 <sup>a</sup>	Impact of 18F-fluoroestradiol (FES) Positron Emission Tomography (PET) on the Therapeutic Treatment of Metastatic Breast Cancer Inpatients, Initially ER Positive and HER2 Negative, in Relapse After First-line Therapy Combining Hormone Therapy	152	Jun 2025
NCT01737619	Prospective Evaluation of Lymph Node Metastasis At the Time of Surgical Staging for High Risk Endometrial Cancer	150	Apr 2025
NCT05088785	Dynamic and Test-retest Whole Body [18F]FES PET Imaging in Patients With Metastatic ER+ Breast Cancer	15	Apr 2025
NCT05613270	A Prospective Pilot Study to Explore Performance and Efficacy of 18F-FES PET/CT in ER-positive Breast Cancer Patients	50	Dec 2024
NCT02409316	[18F]Fluoroestradiol (FES) PET/CT Imaging to Evaluate in Vivo ER in Endocrine Refractory Metastatic Breast Cancer	6	Dec 2024 (active, not recruiting)
NCT03442504	Evaluation Study of the Prediction of the Response to Second-line Hormone Therapy by 16 $\alpha$ - [18F] Fluoro-17 $\beta$ -estradiol (FES) PET in Patients With Metastatic Breast Cancer	57 (actual)	Jun 2024 (active, not recruiting)



<b>NCT No.</b>	<b>Trial Name</b>	<b>Planned Enrollment</b>	<b>Completion Date</b>
NCT05056259	Usefulness of 18F-FDG PET/CT in the Initial Staging and Surveillance of Endometrial Cancer Patients	42	Oct 2023 (unknown status)
<b><i>Unpublished</i></b>			
NCT01916122	Fluorestradiol (FES) PET/CT for Imaging Estrogen Receptor Status	54 (actual)	Apr 2024
NCT03726931	FES (16 $\alpha$ -[18F]-Fluoro-17 $\beta$ -estradiol)-PET: Towards a New Standard to Stage Locally Advanced and Recurrent, Estrogen Receptor Positive (ER+) Breast Cancer? Pilot Study to Compare [18F]FES-PET and [18F]FDG-PET	40 (actual)	Jan 2023
<b><i>Terminated</i></b>			
NCT04727632	[18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE: Functional Precision Oncology for Metastatic Breast Cancer Feasibility Trial	2 (actual)	Jul 2024 (terminated; it was not feasible to perform FES PET/CT)
NCT02149173	Serial [F-18] Fluoroestradiol (FES) PET Imaging to Evaluate Endocrine-Targeted Therapy	29 (actual)	Jan 2021 (terminated due to low accrual)
NCT02317302	FDG Tumor Heterogeneity During Chemoradiation as a Predictor of Response to Concurrent Radiation Therapy and Chemotherapy in Patients With Cervical Cancer	48 (actual)	Jun 2020 (terminated; insufficient funding)
NCT00816582	A Phase II Clinical Trial to Evaluate 18F-Fluoroestradiol Positron Emission Tomography / Computerized Tomography (PET/CT) Guided Fulvestrant Therapy for Patients With Recurrent or Metastatic Breast Cancer	17 (actual)	Jul 2018 (terminated; slow accrual)

NCT: national clinical trial.

<sup>a</sup> Denotes industry-sponsored or cosponsored trial.

**CODING**

**The following codes for treatment and procedures applicable to this policy are included below for informational purposes. This may not be a comprehensive list of procedure codes applicable to this policy.**

**Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.**

**The code(s) listed below are medically necessary ONLY if the procedure is performed according to the "Policy" section of this document.**

<b>CPT/HCPCS</b>	
78608	Brain imaging, positron emission tomography (PET); metabolic evaluation
78609	Brain imaging, positron emission tomography (PET); perfusion evaluation
78811	Positron emission tomography (PET) imaging; limited area (e.g. Chest, head/neck)
78812	Positron emission tomography (PET) imaging; skull base to mid-thigh
78813	Positron emission tomography (PET) imaging; whole body
78814	Tumor imaging, positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization; limited area (e.g. chest, head/neck)
78815	Tumor imaging, positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization; skull base to mid-thigh
78816	Tumor imaging, positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization; whole body
A9591	Fluoroestradiol F-18, diagnostic, 1 mCi
A9552	Fluorodeoxyglucose F-18 FDG, diagnostic, per study dose, up to 45 millicuries
A9597	Positron emission tomography radiopharmaceutical, diagnostic, for tumor identification, not otherwise classified
A9598	Positron emission tomography radiopharmaceutical, diagnostic, for non-tumor identification, not otherwise classified
G0235	PET imaging, any site not otherwise specified
G0252	PET imaging, full and partial-ring PET scanners only, for initial diagnosis of breast cancer and/or surgical planning for breast cancer (eg, initial staging of axillary lymph nodes).

<b>REVISIONS</b>	
Posted 01-28-2025 Effective 02-27-2025	Oncologic Applications Breast and Gynecologic was originally part of the Positron Emission Tomography (PET) Scanning: Oncologic Applications medical policy. Oncologic Applications for Breast and Gynecologic has been pulled out and placed into a separate medical policy, Positron Emission Tomography (PET) Scanning: Oncologic Applications (Breast and Gynecologic). The medical policy language was updated with the changes noted below.
	Updated Description section.

<b>REVISIONS</b>	
	<p>Updated Policy Section</p> <ul style="list-style-type: none"> <li>▪ Section A Breast Cancer Added: "using <sup>18</sup>F-FDG isotope" to section A1 and A2</li> <li>▪ Added Section A3: "PET scanning using fluoroestradiol F18 (FES) is considered experimental / investigational in individuals with breast cancer (see Policy Guidelines for exceptions)"</li> <li>▪ Section B Cervical Cancer Added: "using <sup>18</sup>F-FDG isotope" to section B1 and B2</li> <li>▪ Section C Endometrial Cancer Added: "using <sup>18</sup>F-FDG isotope" to section C1</li> <li>▪ Section D Ovarian Cancer Added: "using <sup>18</sup>F-FDG isotope" to section D1 and D2</li> </ul>
	<p>Updated Policy Guidelines</p> <ul style="list-style-type: none"> <li>▪ Added Policy Guideline D: "Use of fluoroestradiol F18 (FES)-PET may be considered in individuals with recurrent or metastatic breast cancer in certain clinical scenarios, such as when a biopsy is inconclusive. Current NCCN guidelines on breast cancer (v.5.2024) state that FES-PET may be considered for estrogen receptor-positive disease."</li> </ul>
	Updated Rationale section.
	<p>Updated Coding section.</p> <ul style="list-style-type: none"> <li>▪ Added A9591</li> </ul>
	Updated Reference section.

## REFERENCES

1. Centers for Medicare & Medicaid Services (CMS). 2013. Pub 100-03 National Coverage Determination (NCD) for Positron Emission TOMOGRAPHY (FDG) for Oncologic Conditions (220.6.17). <https://tinyurl.com/7hc7hvpr>. Accessed November 7, 2024.
2. Liang X, Yu J, Wen B, et al. MRI and FDG-PET/CT based assessment of axillary lymph node metastasis in early breast cancer: a meta-analysis. *Clin Radiol*. Apr 2017; 72(4): 295-301. PMID 28139203
3. Caldarella C, Treglia G, Giordano A. Diagnostic performance of dedicated positron emission mammography using fluorine-18-fluorodeoxyglucose in women with suspicious breast lesions: a meta-analysis. *Clin Breast Cancer*. Aug 2014; 14(4): 241-8. PMID 24472718
4. Sloka JS, Hollett PD, Mathews M. A quantitative review of the use of FDG-PET in the axillary staging of breast cancer. *Med Sci Monit*. Mar 2007; 13(3): RA37-46. PMID 17325645
5. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). Positron Emission Tomography in Breast Cancer. *Technol Eval Cent Assess*. 2001;16(5).
6. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). FDG Positron Emission Tomography for Evaluating Breast Cancer. *Technol Eval Cent Assess*. 2003;18(14).
7. Zamanian M, Treglia G, Abedi I. Diagnostic Accuracy of PET with Different Radiotracers versus Bone Scintigraphy for Detecting Bone Metastases of Breast Cancer: A Systematic Review and a Meta-Analysis. *J Imaging*. Dec 08 2023; 9(12). PMID 38132692
8. Han S, Choi JY. Impact of 18F-FDG PET, PET/CT, and PET/MRI on Staging and Management as an Initial Staging Modality in Breast Cancer: A Systematic Review and Meta-analysis. *Clin Nucl Med*. Apr 01 2021; 46(4): 271-282. PMID 33651022
9. Hong S, Li J, Wang S. 18FDG PET-CT for diagnosis of distant metastases in breast cancer patients. A meta-analysis. *Surg Oncol*. Jun 2013; 22(2): 139-43. PMID 23566435

10. Rong J, Wang S, Ding Q, et al. Comparison of 18 FDG PET-CT and bone scintigraphy for detection of bone metastases in breast cancer patients. A meta-analysis. *Surg Oncol*. Jun 2013; 22(2): 86-91. PMID 23726506
11. Isasi CR, Moadel RM, Blaufox MD. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. *Breast Cancer Res Treat*. Mar 2005; 90(2): 105-12. PMID 15803356
12. Xiao Y, Wang L, Jiang X, et al. Diagnostic efficacy of 18F-FDG-PET or PET/CT in breast cancer with suspected recurrence: a systematic review and meta-analysis. *Nucl Med Commun*. Nov 2016; 37(11): 1180-8. PMID 27428888
13. Liu Q, Wang C, Li P, et al. The Role of (18)F-FDG PET/CT and MRI in Assessing Pathological Complete Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer: A Systematic Review and Meta-Analysis. *Biomed Res Int*. 2016; 2016: 3746232. PMID 26981529
14. Sheikhabahaei S, Trahan TJ, Xiao J, et al. FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies. *Oncologist*. Aug 2016; 21(8): 931-9. PMID 27401897
15. Li H, Yao L, Jin P, et al. MRI and PET/CT for evaluation of the pathological response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis. *Breast*. Aug 2018; 40: 106-115. PMID 29758503
16. Cheng X, Li Y, Liu B, et al. 18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis. *Acta Radiol*. Jul 2012; 53(6): 615-27. PMID 22734080
17. Wang Y, Zhang C, Liu J, et al. Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis. *Breast Cancer Res Treat*. Jan 2012; 131(2): 357-69. PMID 21960111
18. Kurland BF, Wiggins JR, Coche A, et al. Whole-Body Characterization of Estrogen Receptor Status in Metastatic Breast Cancer with 16 $\alpha$ -18F-Fluoro-17 $\beta$ -Estradiol Positron Emission Tomography: Meta-Analysis and Recommendations for Integration into Clinical Applications. *Oncologist*. Oct 2020; 25(10): 835-844. PMID 32374053
19. Gennari A, Brain E, De Censi A, et al. Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with 18 F-fluoroestradiol ( 18 F-FES) CT/PET. *Ann Oncol*. Jun 2024; 35(6): 549-558. PMID 38423389
20. Ulaner GA, Silverstein M, Nangia C, et al. ER-Targeted PET for Initial Staging and Suspected Recurrence in ER-Positive Breast Cancer. *JAMA Netw Open*. Jul 01 2024; 7(7): e2423435. PMID 39058489
21. van Geel JJJ, Boers J, Elias SG, et al. Clinical Validity of 16 $\alpha$ -[ 18 F]Fluoro-17 $\beta$ -Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer. *J Clin Oncol*. Nov 01 2022; 40(31): 3642-3652. PMID 35584346
22. Chae SY, Ahn SH, Kim SB, et al. Diagnostic accuracy and safety of 16 $\alpha$ -[ 18 F]fluoro-17 $\beta$ -oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study. *Lancet Oncol*. Apr 2019; 20(4): 546-555. PMID 30846327
23. Moy L, Bailey L, D'Orsi C, et al. ACR Appropriateness Criteria  $\text{\textcircled{R}}$  Stage I Breast Cancer: Initial Workup and Surveillance for Local Recurrence and Distant Metastases in Asymptomatic Women. *J Am Coll Radiol*. May 2017; 14(5S): S282-S292. PMID 28473085

24. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 5.2024.  
[https://www.nccn.org/professionals/physician\\_gls/pdf/breast.pdf](https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf). Accessed November 7, 2024.
25. Ulaner GA, Mankoff DA, Clark AS, et al. Summary: Appropriate Use Criteria for Estrogen Receptor-Targeted PET Imaging with  $^{18}\text{F}$ -Fluoro- $^{17}\beta$ -Fluoroestradiol. *J Nucl Med*. Mar 2023; 64(3): 351-354. PMID 36863779
26. Chu Y, Zheng A, Wang F, et al. Diagnostic value of  $^{18}\text{F}$ -FDG-PET or PET-CT in recurrent cervical cancer: a systematic review and meta-analysis. *Nucl Med Commun*. Feb 2014; 35(2): 144-50. PMID 24177043
27. Ospina MB, Horton J, Seida J, et al. Technology Assessment Report : Positron emission tomography for nine cancers (bladder, brain, cervical, kidney, ovarian, pancreatic, prostate, small cell lung, testicular). Rockville, MD: Agency for Healthcare Research and Quality; 2008.
28. Yen TC, See LC, Chang TC, et al. Defining the priority of using  $^{18}\text{F}$ -FDG PET for recurrent cervical cancer. *J Nucl Med*. Oct 2004; 45(10): 1632-9. PMID 15471826
29. Podoloff DA, Ball DW, Ben-Josef E, et al. NCCN task force: clinical utility of PET in a variety of tumor types. *J Natl Compr Canc Netw*. Jun 2009; 7 Suppl 2: S1-26. PMID 19555588
30. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer. Version 4.2024.  
[https://www.nccn.org/professionals/physician\\_gls/pdf/cervical.pdf](https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf). Accessed November 6, 2024.

#### **OTHER REFERENCES**

1. MCMC, Medical Care Ombudsman Program (MCOP), August 11, 2006, MCOP ID 1071-0720.
2. Considine oncology consultant (#372), January 23, 2007, Reference: *Semin Nucl Med*. 2006 Jan;36(1):93-104. Links Positron emission tomography in gynecologic cancer. Yen TC, Lai CH.
3. Blue Cross and Blue Shield of Kansas, Oncology Liaison Committee meeting, February 2003, February 2004, June 2022, July 2023.
4. Blue Cross and Blue Shield of Kansas, Radiology Liaison Committee meeting, February 2002, February 2003. February 2009, January 2018, May 2019.
5. Blue Cross and Blue Shield of Kansas Urology Liaison Committee August 2018, June 2020.